本文已被：浏览 692次 下载 384次
投稿时间：2020-04-10 网络发布日期：2020-12-20
投稿时间：2020-04-10 网络发布日期：2020-12-20
中文摘要: 目的 观察化瘀复元胶囊对冠心病经皮冠状动脉介入术(PCI)治疗后患者血管内皮因子、炎症因子及临床疗效的影响。方法 将2019年1月至2019年6月冠心病血瘀证患者50例随机分为治疗组和对照组，每组25例。治疗组在对照组常规治疗的基础上加用化瘀复元胶囊，疗程为7 d。对比两组治疗前、治疗后24 h、治疗后7 d血管内皮因子［血管性假性血友病因子(vWF)、内皮素-1(ET-1)、一氧化氮(NO)］、炎症因子［高敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、白介素-6(IL-6)］的变化，观察两组治疗前后中医证候积分变化及临床疗效。结果 (1)治疗后24 h，两组患者NO水平下降，vWF、ET-1、hs-CRP、TNF-α、IL-6水平均升高，与治疗前比较差异均有统计学意义(P<0.05)，组间比较，差异均无统计学意义(P>0.05)。治疗后7 d，两组患者NO水平逐渐升高，vWF、ET-1、hs-CRP、TNF-α、IL-6水平逐渐降低，与治疗后24 h比较，差异均有统计学意义(P<0.05)，而与治疗前相比，NO、vWF、ET-1、TNF-α、IL-6水平差异有统计学意义(P<0.05)，hs-CRP水平差异无统计学意义(P>0.05)，组间比较，治疗组上述各项指标的改善优于对照组，差异有统计学意义(P<0.05，P<0.01)。(2)治疗组中医证候积分的改善优于对照组(P<0.05)，临床疗效亦优于对照组(P<0.05)。结论 化瘀复元胶囊可以有效改善行PCI后患者的临床症状，无明显副作用，其机制可能与改善行PCI后血管内皮损伤及减轻炎症反应有关。
Abstract:Objective To observe the influences of Huayu Fuyuan capsule on vascular endothelial factor, inflammatory factor and clinical efficacy in patients with coronary heart disease(CHD) after percutaneous coronary intervention (PCI). Methods Fifty CHD patients with blood stasis syndrome from January 2019 to June 2019 were randomly divided into treatment group and control group (n=25, each).On the basis of conventional treatment for 7 days in both groups, Huayu Fuyuan capsule was added in treatment group.The changes of vascular endothelial factor ［von Willebrand factor (vWF), endothelin-1 (ET-1), nitric oxide (NO)］and inflammatory factors ［high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α(TNF-α), interneukin-6(IL-6)］ were observed before treatment, 24- hour after PCI and 7 days after PCI and compared between two groups. TCM syndrome score and clinical efficacy were compared between two groups before and after treatment. Results Compared with those before operation, the level of NO decreased, and the levels of vWF, ET-1, hs-CRP, TNF-α and IL-6 increased statistically at 24 h after operation in two groups(all P<0.05), but there were no significant differences in them between two groups (all P>0.05).At 7 days after treatment, the level of NO increased, and the levels of vWF, ET-1, hs-CRP, TNF-α, IL-6 gradually decreased compared with those at postoperative 24 hours in both groups(P<0.05); compared with those before treatment, there were significantly differences in the levels of NO, vWF, ET-1, TNF-α and IL-6(P<0.05), but not in the level of hs-CRP(P>0.05).The improvement in the above mentioned indexes in treatment group was better than that in control group (P<0.05, P<0.01).TCM syndrome score and clinical efficacy in treatment group were significantly superior to those in control group (P<0.05). Conclusion Huayu Fuyuan capsule can effectively improve the clinical symptoms of CHD patients after PCI without obvious side effects, and the mechanism may be related to its effects on reducing vascular endothelial injury and inflammatory reaction after PCI.
keywords: Coronary heart disease Percutaneous coronary intervention Huayu Fuyuan capsule Vascular endothelial function Inflammatory factors
文章编号： 中图分类号：R256.2，R543.3 文献标志码：B
基金项目:南通市科技局科研立项(指导)课题(MSZ18266)
| Author Name | Affiliation |
| GU Yong-qing, LI Xiao-qian, ZHENG Xiao-dan, YAO Zu-pei | Department of Cardiovascular Diseases, Nantong Hospital of Traditional Chinese Medicine, Nantong, Jiangsu 226001, China |
引用文本：
顾勇清，李晓倩，郑晓丹，姚祖培.化瘀复元胶囊对冠心病PCI治疗后血管内皮因子及炎症因子的影响[J].中国临床研究,2020,33(12):1676-1680.
顾勇清，李晓倩，郑晓丹，姚祖培.化瘀复元胶囊对冠心病PCI治疗后血管内皮因子及炎症因子的影响[J].中国临床研究,2020,33(12):1676-1680.